Function of RELMβ in oral tolerance breakdown in food allergy
Function of RELMβ in oral tolerance breakdown in food allergy
批准号:
10621812
负责人:
Elena Crestani
金额:
$19.49万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-06-09 至 2026-05-31
关键词:
AffectAgeAllergensAllergicAllergic DiseaseAnaphylaxisAsthmaAtopic DermatitisAwardBiological MarkersBiometryCaringCellsChildChildhoodClinicalClinical effectivenessCommunitiesData AnalysesDevelopmentDiagnosisDiseaseDisease OutcomeEnvironmentEnvironmental Risk FactorEpidemicEpidemiologyEquilibriumEvaluationFive-Year PlansFoodFood HypersensitivityFoundationsFrequenciesFundingFutureGATA3 geneGenerationsGeneticGoalsHeadHealthHumanIgEImmuneImpairmentIndividualInstitutionInterleukin-4InvestigationKnowledgeLaboratoriesLearningLifeLife StyleMaster of Public HealthMediatingMentorsModernizationMolecularMucous MembraneMusPathogenesisPathogenicityPatientsPhysiciansPlasmaPlayPositioning AttributePrevalenceProductionPublic HealthPublic Health SchoolsQuality of lifeRegulationRegulatory T-LymphocyteResearchResearch PersonnelResolutionResourcesRiskRoleScientistSerumSeveritiesSignal TransductionT cell responseTechniquesTestingTherapeutic InterventionTimeTrainingTranslationsUnited States National Institutes of HealthWorkallergic responsebiomarker developmentbiomarker discoverycandidate markercareercareer developmentclinical applicationclinical investigationcohortcurative treatmentsenteric pathogenfood protectiongut microbiomeimprovedmast cellmetabolomicsmicrobial compositionmicrobiomemicrobiome compositionmouse allergymouse modelnovelnovel markernovel therapeutic interventionoral toleranceresistinresponseskillssymposiumtargeted treatment
中文摘要
项目总结/摘要:
研究:食物过敏是一种潜在的危及生命的健康状况,影响越来越多的人,
仅在美国的个人。目前对食物过敏患者的日常管理受到
缺乏可靠的生物标志物来准确预测疾病的发作、严重程度和消退,
缺乏治疗方法来取代严格避免罪魁祸首食物。更深入地了解其他
在食物过敏发病机制中起作用的IgE以外的其他机制将是填补这些空白的关键。这项建议
详细介绍了一个五年计划,为Crestani博士提供培训和专业知识,以评估CIMb的作用,
一种新的生物标志物和分子球员在食物过敏建设和扩大强初步
在食物过敏的小鼠模型和食物过敏儿童中的观察。综合评价
食物过敏中的抗组胺抗体的作用,有希望确定强烈需要的疾病生物标志物(S)
和治疗干预的可能目标,这将是未来纵向研究的重点,
可能会显著影响食物过敏患者的日常护理和生活质量。
Crestani博士的长期目标是成为一名独立的,NIH资助的研究人员,专注于
食物过敏的疾病机制和生物标志物,目的是改善目前的次优护理,
食物过敏的人。对新的生物标志物和治疗方法存在迫切且未满足的需求
食物过敏为了实现这一目标,她的短期目标是获得生物统计学、数据
分析,实验室技术,以及在队列建设和管理的实践技能。这将是
通过正式课程、协作工作、参加会议和既定的指导完成学业。
具有相关专业知识的导师/科学顾问。这将导致实践技能的独特组合,
科学知识,这将成功地定位她的R 01应用程序和独立的职业生涯,作为一个
食物过敏领域的医生兼科学家
环境:Crestani博士将由Chatila博士(主要导师)指导,Chatila博士是以下领域的主要研究者:
食物过敏的机制和一个完全由NIH资助的实验室的负责人,Phipatanakul博士(共同导师),一个
流行病学、人类队列和哮喘及过敏性疾病临床研究专家。克雷斯塔尼医生
已经组建了一个非凡的顾问团队,包括琳达·施耐德博士、卡莉·纳多博士和瑞玛博士。
Kaddurah-Daouk,他们投入了时间,资源和专业知识来促进Crestani博士的职业生涯
发展和顺利完成拟议项目。在此期间,Crestani博士将
通过哈佛公共卫生学院(HSPH)获得临床有效性公共卫生硕士学位,
并完成额外的补充课程。导师们创造的学术环境,
整个机构和哈佛社区将为学习和研究提供理想的环境
能保证克雷斯塔尼医生成为一名非常成功的独立调查员
英文摘要
PROJECT SUMMARY/ABSTRACT:
Research: Food allergy is a potentially life-threatening health condition that affects an increasing proportion of
individuals in the US alone. Current daily management of patients with food allergies is limited by the
unavailability of reliable biomarkers to accurately predict onset, severity and resolution of disease, and by the
lack of curative treatments to replace strict avoidance of the culprit food. A deeper understanding of additional
mechanisms - other than IgE - acting in food allergy pathogenesis will be key in filling these gaps. This proposal
details a five-year plan to provide Dr. Crestani with the training and expertise to evaluate the role of RELMb as
a novel biomarker and molecular player in food allergy building and expanding on strong preliminary
observations both in a murine model of food allergy and in food allergic children. The comprehensive evaluation
of the role of RELMb in food allergy holds the promise of identifying strongly needed biomarker(s) of disease
and possible targets for therapeutic interventions which will be the focus of future longitudinal investigations and
may significantly impact the daily care and quality of life of food allergic patients.
Candidate: Dr. Crestani long-term goal is to become an independent, NIH-funded investigator focused on
disease mechanisms and biomarkers of food allergy, with the goal of improving the currently suboptimal care of
food-allergic individuals. There is an urgent and unmet need for novel biomarkers and therapeutic approaches
in food allergies. To achieve this goal, her short-term objectives are to obtain further training in biostatistics, data
analysis, laboratory techniques, as well as practical skills in cohort building and management. This will be
accomplished with formal classes, collaborative work, attendance at conferences, and guidance from established
mentors/scientific advisors with relevant expertise. This will result in a unique combination of practical skills and
scientific knowledge that will successfully position her for an R01 application and an independent career as a
physician-scientist in the field of food allergy.
Environment: Dr. Crestani will be mentored by Dr. Chatila (Primary Mentor), a leader investigator in
mechanisms of food allergy and head of a fully NIH-funded laboratory, and Dr. Phipatanakul (Co-Mentor), an
expert in epidemiology, human cohorts, and clinical investigation in asthma and allergic diseases. Dr. Crestani
has assembled an extraordinary team of advisors, including Drs. Lynda Schneider, Kari Nadeau and Rima
Kaddurah-Daouk, who have committed their time, resources, and expertise to facilitate Dr. Crestani’s career
development and successful completion of the proposed project. During this award period, Dr. Crestani will
obtain a Master of Public Health in Clinical Effectiveness through the Harvard School of Public Health (HSPH),
and complete additional complementary coursework. The academic environment created by the mentors,
institution, and Harvard community at large will provide the ideal milieu for learning and research implementation
that will guarantee Dr. Crestani transition into a highly successful independent investigator.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Function of RELMβ in oral tolerance breakdown in food allergy
-
批准号:10301157
-
项目类别:
-
资助金额:$19.49万
-
财政年份:2021
-
负责人:Elena Crestani
-
依托单位:
Function of RELMβ in oral tolerance breakdown in food allergy
-
批准号:10424584
-
项目类别:
-
资助金额:$19.49万
-
财政年份:2021
-
负责人:Elena Crestani
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: